We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Zacks Research raised its Q3 2025 earnings estimate for Pfizer from $0.83 to $0.90 per share. Analysts predict full-year ...

Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...

Pfizer’s earnings have been struggling for the past three years, with its stock down 43%, well behind the market’s 38% return. Over the last three years, Pfizer’s earnings per share (EPS) dropped 29% ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

(NYSE:PFE) shareholders, since the share price is down 43% in the last three years, falling well short of the market return ...

Pfizer Ltd notched up volume of 9.3 lakh shares by 14:14 IST on NSE, a 18.12 fold spurt over two-week average daily volume of 51359 shares. The stock rose 5.50% to Rs.4,320.35. Volumes stood at 16716 ...

Turnover at catering company was boosted by increased sales and the addition of some new contracts to the business ...

It is a five-year agreement that was effective upon approval by Pfizer’s Board of Directors on February 21, 2025.

While smokable product sales are declining slowly, sales of non-smokable products are driving growth for Altria Group. The ...